左甲状腺素治疗亚临床甲状腺功能减退症合并心脏病患者的长期结局
该研究为丹麦注册库历史队列研究,纳入1997-2011年确诊亚临床甲状腺功能减退症且已患心脏病的初级保健与医院门诊患者1192例(平均年龄73.6岁,女性63.8%),其中136例(11.4%)接受左甲状腺素治疗。中位随访5.6年期间694例(58.2%)死亡;与未治疗者相比,左甲状腺素治疗与全因死亡、主要不良心血管事件(MACE)及住院风险均无显著相关。
要点
- 合并心脏病的亚临床甲状腺功能减退症患者中,11.4%(136/1192)接受左甲状腺素治疗。
- 左甲状腺素治疗与全因死亡风险无显著相关(校正IRR 1.17;95%CI 0.90-1.52)。
- 左甲状腺素治疗与MACE(校正IRR 1.08;95%CI 0.80-1.45)及住院(校正IRR 0.94;95%CI 0.71-1.24)均无显著相关。
核心结论
- 在合并心脏病的亚临床甲状腺功能减退症患者中,左甲状腺素治疗与全因死亡、MACE或住院的显著获益或风险均无关。
研究设计与样本
- 丹麦注册库历史队列研究,纳入1997-2011年在初级保健和医院门诊确诊亚临床甲状腺功能减退症、年龄18岁及以上且已确诊心脏病的患者。
- 共纳入1192例患者(平均年龄73.6岁,标准差±13.3岁,女性63.8%),按是否随后领取左甲状腺素处方分层,其中136例(11.4%)接受左甲状腺素治疗。
- 采用时间依存多变量泊松回归模型计算事件率与发病率比(IRR)。
主要发现
- 中位随访5.6年(四分位距6.5年)期间,694例(58.2%)死亡。
- 与未接受左甲状腺素治疗者相比,接受治疗者的全因死亡校正IRR为1.17(95%CI 0.90-1.52)。
- 与未接受左甲状腺素治疗者相比,接受治疗者的MACE校正IRR为1.08(95%CI 0.80-1.45)。
- 与未接受左甲状腺素治疗者相比,接受治疗者的住院校正IRR为0.94(95%CI 0.71-1.24)。
关键数值与推荐
- MACE定义为心血管死亡、致死性或非致死性心肌梗死及卒中。
- 主要结局包括全因死亡、MACE和全因住院。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Subclinical hypothyroidism is a common condition that may lead to impaired cardiac function. OBJECTIVE: This study sought to examine the effects of levothyroxine treatment in patients with subclinical hypothyroidism and heart disease. DESIGN: This was a register-based historical cohort study. SETTING AND PARTICIPANTS: The study was composed of Danish primary care patients and hospital outpatients age 18 years and older with established heart disease who were diagnosed with subclinical hypothyroidism in 1997-2011. Patients were stratified according to whether they claimed a subsequent prescription of levothyroxine. Event rates and incidence rate ratios (IRR) were calculated by use of time-dependent multivariable Poisson regression models. MAIN OUTCOME MEASURES: Measures included all-cause mortality and major adverse cardiac events (MACEs), defined as cardiovascular death, fatal or nonfatal myocardial infaction and stroke, and all-cause hospital admissions. RESULTS: Of 61 611 patients with a diagnosis of cardiac disease having their first time thyroid function testing, 1192 patients with subclinical hypothyroidism (mean age 73.6 [SD ± 13.3] y, 63.8% female) were included, of whom 136 (11.4%) were treated with levothyroxine. During a median follow-up time of 5.6 y (interquartile range, 6.5 y), 694 (58.2%) patients died. Patients treated with levothyroxine displayed no significantly increased risk of all-cause mortality (adjusted IRR, 1.17; 95% confidence interval [CI], 0.90-1.52), MACE (adjusted IRR, 1.08; 95% CI, 0.80-1.45), or hospital admission (adjusted IRR, 0.94; 95% CI, 0.71-1.24), when compared with patients not treated with levothyroxine. CONCLUSION: Levothyroxine treatment in patients with subclinical hypothyroidism and heart disease was not associated with a significant benefit nor risk of all-cause mortality, MACE, or hospital admission in this large real-world cohort study.
引用
- Andersen MN, Olsen AS, Madsen JC, et al. Long-Term Outcome in Levothyroxine Treated Patients With Subclinical Hypothyroidism and Concomitant Heart Disease. J Clin Endocrinol Metab. 2016. PMID: 27571183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。